We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Retracts Refuse-to-File Letter Sent to Alkermes in March
FDA Retracts Refuse-to-File Letter Sent to Alkermes in March
The FDA rescinded a refuse-to-file letter it issued to Alkermes in March for the company’s experimental treatment for depressive disorder, the company announced Monday.